Bio-Connect

InVivoPlus anti-mouse TIM-3 (CD366)

BP0115
Bio X Cell
ApplicationsFlow Cytometry, Neutralisation/Blocking
Product group Antibodies
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    Bio X Cell
  • Product Name
    InVivoPlus anti-mouse TIM-3 (CD366)
  • Delivery Days Customer
    7
  • Applications
    Flow Cytometry, Neutralisation/Blocking
  • Certification
    Research Use Only
  • Clonality
    Monoclonal
  • Clone ID
    RMT3-23
  • Concentration
    4-11 mg/ml
  • Estimated Purity
    >95%
  • Host
    Rat
  • Isotype
    IgG2a
  • Storage Instruction
    2°C to 8°C
  • UNSPSC
    12352203

References

  • Liu JF, Wu L, Yang LL, et al. Blockade of TIM3 relieves immunosuppression through reducing regulatory T cells in head and neck cancer. J Exp Clin Cancer Res. 2018,37(1):44. doi: 10.1186/s13046-018-0713-7
    Read this paper
  • Kurtulus S, Sakuishi K, Ngiow SF, et al. TIGIT predominantly regulates the immune response via regulatory T cells. J Clin Invest. 2015,125(11):4053-62. doi: 10.1172/JCI81187
    Read this paper
  • Ngiow SF, Young A, Jacquelot N, et al. A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1. Cancer Res. 2015,75(18):3800-11. doi: 10.1158/0008-5472.CAN-15-1082
    Read this paper
  • Tripathi S, Chabtini L, Dakle PJ, et al. Effect of TIM-3 Blockade on the Immunophenotype and Cytokine Profile of Murine Uterine NK Cells. PLoS One. 2015,10(4):e0123439. doi: 10.1371/journal.pone.0123439
    Read this paper
  • Erickson JJ, Rogers MC, Hastings AK, et al. Programmed death-1 impairs secondary effector lung CD8⁺ T cells during respiratory virus reinfection. J Immunol. 2014,193(10):5108-17. doi: 10.4049/jimmunol.1302208
    Read this paper
  • Mittal D, Young A, Stannard K, et al. Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor. Cancer Res. 2014,74(14):3652-8. doi: 10.1158/0008-5472.CAN-14-0957
    Read this paper
  • Dolina JS, Braciale TJ, Hahn YS. Liver-primed CD8+ T cells suppress antiviral adaptive immunity through galectin-9-independent T-cell immunoglobulin and mucin 3 engagement of high-mobility group box 1 in mice. Hepatology. 2014,59(4):1351-65. doi: 10.1002/hep.26938
    Read this paper
  • Dietze KK, Zelinskyy G, Liu J, et al. Combining regulatory T cell depletion and inhibitory receptor blockade improves reactivation of exhausted virus-specific CD8+ T cells and efficiently reduces chronic retroviral loads. PLoS Pathog. 2013,9(12):e1003798. doi: 10.1371/journal.ppat.1003798
    Read this paper
  • McGray AJ, Hallett R, Bernard D, et al. Immunotherapy-induced CD8+ T cells instigate immune suppression in the tumor. Mol Ther. 2014,22(1):206-18. doi: 10.1038/mt.2013.255
    Read this paper
  • Zelinskyy G, Myers L, Dietze KK, et al. Virus-specific CD8+ T cells upregulate programmed death-1 expression during acute friend retrovirus infection but are highly cytotoxic and control virus replication. J Immunol. 2011,187(7):3730-7. doi: 10.4049/jimmunol.1101612
    Read this paper